These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1975502)

  • 1. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
    Coley HM; Twentyman PR; Workman P
    Eur J Cancer; 1990; 26(6):665-7. PubMed ID: 1975502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
    Coley HM; Twentyman PR; Workman P
    Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efflux of anthracyclines in multidrug-resistant cell lines.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
    Coley HM; Amos WB; Twentyman PR; Workman P
    Br J Cancer; 1993 Jun; 67(6):1316-23. PubMed ID: 8099807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
    Coley HM; Twentyman PR; Workman P
    Cancer Chemother Pharmacol; 1989; 24(5):284-90. PubMed ID: 2547527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
    Coley HM; Workman P; Twentyman PR
    Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).
    Jensen PB; Vindeløv L; Roed H; Demant EJ; Sehested M; Skovsgaard T; Hansen HH
    Br J Cancer; 1989 Dec; 60(6):838-44. PubMed ID: 2574988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
    Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
    Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.
    Cole SP
    Cancer Chemother Pharmacol; 1990; 26(4):250-6. PubMed ID: 1973363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.
    Ramachandran C; Sauerteig A; Sridhar KS; Thurer RJ; Krishan A
    Cancer Chemother Pharmacol; 1993; 31(6):431-41. PubMed ID: 8095859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
    Lee FY; Sciandra J; Siemann DW
    Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
    Michieli M; Michelutti A; Damiani D; Pipan C; Raspadori D; Lauria F; Baccarani M
    Leuk Lymphoma; 1993 Feb; 9(3):255-64. PubMed ID: 8097129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
    Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
    Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of doxorubicin-resistant Lewis lung carcinoma variants.
    Bruno NA; Carver LA; Slate DL
    Cancer Commun; 1990; 2(4):151-8. PubMed ID: 1973357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R.
    Rhodes T; Barrand MA; Twentyman PR
    Br J Cancer; 1994 Jul; 70(1):60-6. PubMed ID: 7912544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation.
    Llagostera E; Soto-Cerrato V; Joshi R; Montaner B; Gimenez-Bonafé P; Pérez-Tomás R
    Anticancer Drugs; 2005 Apr; 16(4):393-9. PubMed ID: 15746575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
    Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
    Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.